NasdaqGS:TRIB

Stock Analysis Report

Executive Summary

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe.

Snowflake

Fundamentals

Fair value with imperfect balance sheet.


Similar Companies

Share Price & News

How has Trinity Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRIB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.2%

TRIB

0.9%

US Medical Equipment

-0.2%

US Market


1 Year Return

-65.6%

TRIB

23.0%

US Medical Equipment

16.1%

US Market

Return vs Industry: TRIB underperformed the US Medical Equipment industry which returned 23% over the past year.

Return vs Market: TRIB underperformed the US Market which returned 16.1% over the past year.


Shareholder returns

TRIBIndustryMarket
7 Day1.2%0.9%-0.2%
30 Day44.3%5.4%3.7%
90 Day-31.0%4.7%8.5%
1 Year-65.6%-65.6%24.1%23.0%18.7%16.1%
3 Year-85.3%-85.3%88.0%82.4%46.9%37.4%
5 Year-94.1%-94.2%115.7%92.4%61.8%44.0%

Price Volatility Vs. Market

How volatile is Trinity Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trinity Biotech undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TRIB ($1) is trading below our estimate of fair value ($3.88)

Significantly Below Fair Value: TRIB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TRIB is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: TRIB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRIB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRIB is good value based on its PB Ratio (0.5x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Trinity Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

5.5%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TRIB's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if TRIB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TRIB's revenue (5.5% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: TRIB's revenue (5.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TRIB's Return on Equity is forecast to be low in 3 years time (17%).


Next Steps

Past Performance

How has Trinity Biotech performed over the past 5 years?

-51.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRIB has large one-off items impacting its financial results.

Growing Profit Margin: TRIB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRIB is unprofitable, and losses have increased over the past 5 years at a rate of -51.2% per year.

Accelerating Growth: Unable to compare TRIB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRIB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: TRIB has a negative Return on Equity (-77.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Trinity Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: TRIB's short term assets ($81.1M) exceeds its short term liabilities ($25.9M)

Long Term Liabilities: TRIB's short term assets ($81.1M) do not cover its long term liabilities (108.4M)


Debt to Equity History and Analysis

Debt Level: TRIB's debt to equity ratio (207.8%) is considered high.

Reducing Debt: Insufficient data to determine if TRIB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TRIB has a high level of physical assets or inventory.

Debt Coverage by Assets: TRIB's debt is covered by short term assets (assets are 1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRIB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TRIB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Trinity Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TRIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TRIB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: TRIB is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Trinity Biotech's salary, the management and board of directors tenure and is there insider trading?

11.0yrs

Average board tenure


CEO

Ronan O’Caoimh (63yo)

11.1yrs

Tenure

US$585,000

Compensation

Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March  ...


CEO Compensation Analysis

Compensation vs Market: Ronan's total compensation ($USD585.00K) is about average for companies of similar size in the US market ($USD504.52K).

Compensation vs Earnings: Ronan's compensation has been consistent with company performance over the past year.


Board Age and Tenure

11.0yrs

Average Tenure

64yo

Average Age

Experienced Board: TRIB's board of directors are seasoned and experienced ( 11 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Ronan O’Caoimh (63yo)

    Co-Founder

    • Tenure: 11.1yrs
    • Compensation: US$585.00k
  • Jim Walsh (61yo)

    Executive Director

    • Tenure: 12.8yrs
    • Compensation: US$9.00k
  • Kevin Tansley (48yo)

    CFO, Company Secretary & Executive Director

    • Tenure: 3.2yrs
    • Compensation: US$523.00k

Board Members

  • Clint Severson (71yo)

    Non-Executive Director

    • Tenure: 11yrs
    • Compensation: US$75.00k
  • Denis Burger (75yo)

    Non-Executive Director & Lead Director

    • Tenure: 0yrs
  • Ronan O’Caoimh (63yo)

    Co-Founder

    • Tenure: 11.1yrs
    • Compensation: US$585.00k
  • Jim Walsh (61yo)

    Executive Director

    • Tenure: 12.8yrs
    • Compensation: US$9.00k
  • Jim Merselis (65yo)

    Non-Executive Director

    • Tenure: 10.8yrs
    • Compensation: US$75.00k
  • Kevin Tansley (48yo)

    CFO, Company Secretary & Executive Director

    • Tenure: 3.2yrs
    • Compensation: US$523.00k

Company Information

Trinity Biotech plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trinity Biotech plc
  • Ticker: TRIB
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$19.219m
  • Shares outstanding: 20.90m
  • Website: https://www.trinitybiotech.com

Number of Employees


Location

  • Trinity Biotech plc
  • IDA Business Park
  • Bray
  • Co. Wicklow
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRIBNasdaqGS (Nasdaq Global Select)YesADR EACH REPR 4 CLS'A'ORD USD0.019USUSDOct 1992
TRBADB (Deutsche Boerse AG)YesADR EACH REPR 4 CLS'A'ORD USD0.019DEEUROct 1992

Biography

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Afr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 23:47
End of Day Share Price2019/11/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.